Warnex to sell analytical services business

By Gareth Macdonald

- Last updated on GMT

Related tags: Revenue, Income statement, Medical laboratory

Warnex to sell analytical services business
Warnex is to sell its analytical services division to an unnamed private company in the latest move in a drastic restructuring programme.

News of the sale – which values the analytics business at $C$1.1m ($1.07m) – follows weeks after Warnex divested its medical labs arm​.

It also means that Warnex' bioanalytical division, which provides bioequivalence and bioavailability services for clinical trials, will be its only remaining unit in 2012.

Warnex will retain a 15 per cent equity interest in the analytical division, which provides product and facility quality control services for pharma and biotech companies.

The analytical services unit generated C$10.5m, or 47 per cent, of Warnex' total revenue in 2010 but has struggled more recently as a result of declining industry demand.

Strategic review

In response Warnex launched a strategic review of its operations in November shortly before the departure of long-serving CEO Mark Busgang​.

The decision to focus on bioanalytical services looks like a sensible one given that – in contrast with the divested analytical and medical laboratories units – the division has seen revenue and net earnings grow in recent quarters​.

Warnex said that - after the sale is completed in January - the divested unit’s operations will be based at a facility in Blainville, Canada.

Michael Singer, chair of Warnex’ executive review committee, said in a press statement that the deal "allows us to retain substantial upside in the analytical services business that we pioneered.

"The sale of our analytical services division serves as another important step in the process of improving our balance sheet and positioning the company and its stakeholders for future success​" he added.

Related news

Show more

Related products

show more

A Winning End-to-End Solution for Oncology Studies

A Winning End-to-End Solution for Oncology Studies

Clinical Ink | 22-Feb-2021 | Technical / White Paper

Oncology clinical trials present a unique set of challenges for patients, study sites, and study sponsors. Using electronic patient reported outcomes (ePRO)...

Has EDC Kept Up With Changes In Clinical Trials?

Has EDC Kept Up With Changes In Clinical Trials?

Oracle Health Sciences | 14-Dec-2020 | Technical / White Paper

In just a few decades, clinical trials have changed dramatically. Twenty years ago, most of the data used in clinical research was entered on paper, but...

Related suppliers

Follow us


View more